ArticleBMC genomics2008
Global analysis of aberrant pre-mRNA splicing in glioblastoma using exon expression arrays.
Article in BMC genomics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 75 citations in OpenAlex.
- Tumor Protein D53 (TPD53): Involvement in Malignant Transformation of Low-Malignant Oral Squamous Cell Carcinoma Cells.Biomedicines · 2024Article
- A Novel Splice Variant ofCancers · 2022Article
- Identifying the Predictive Role of Oxidative Stress Genes in the Prognosis of Glioma Patients.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- Genome-wide profiling of alternative splicing in glioblastoma and their clinical value.BMC cancer · 2021Article
- Tumor protein D52 is upregulated in oral squamous carcinoma cells under hypoxia in a hypoxia-inducible-factor-independent manner and is involved in cell death resistance.Cell & bioscience · 2021Article
- TPD52L2 Is a Prognostic Biomarker and Correlated With Immune Infiltration in Lung Adenocarcinoma.Frontiers in pharmacology · 2021Article
- RBFOX1 Regulates the Permeability of the Blood-Tumor Barrier via the LINC00673/MAFF Pathway.Molecular therapy oncolytics · 2020Article
- Review
- Specific inhibition of splicing factor activity by decoy RNA oligonucleotides.Nature communications · 2019Article
- The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma.Neuro-oncology · 2018Article
- Revealing the Determinants of Widespread Alternative Splicing Perturbation in Cancer.Cell reports · 2017Article
- Transcriptional signature of lymphoblastoid cell lines ofOncotarget · 2017Article
- RNA processing as an alternative route to attack glioblastoma.Human genetics · 2017Review
- Evaluation of autoantibody signatures in meningioma patients using human proteome arrays.Oncotarget · 2017Article
- Splice variants as novel targets in pancreatic ductal adenocarcinoma.Scientific reports · 2017Article
- MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.Cancer letters · 2016Article
- Identification of recurrent regulated alternative splicing events across human solid tumors.Nucleic acids research · 2015Article
- Identifying the genes regulated by IDH1 via gene-chip in glioma cell U87.International journal of clinical and experimental medicine · 2015Article
- Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression.The Journal of clinical investigation · 2014Article
- A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundTumor-predominant splice isoforms were identified during comparative in silico sequence analysis of EST clones, suggesting that global aberrant alternative pre-mRNA splicing may be an epigenetic phenomenon in cancer. We used an exon expression array to perform an objective, genome-wide survey of glioma-specific splicing in 24 GBM and 12 nontumor brain samples. Validation studies were performed using RT-PCR on glioma cell lines, patient tumor and nontumor brain samples.
resultsIn total, we confirmed 14 genes with glioma-specific splicing; seven were novel events identified by the exon expression array (A2BP1, BCAS1, CACNA1G, CLTA, KCNC2, SNCB, and TPD52L2). Our data indicate that large changes (> 5-fold) in alternative splicing are infrequent in gliomagenesis (< 3% of interrogated RefSeq entries). The lack of splicing changes may derive from the small number of splicing factors observed to be aberrantly expressed.
conclusionWhile we observed some tumor-specific alternative splicing, the number of genes showing exclusive tumor-specific isoforms was on the order of tens, rather than the hundreds suggested previously by in silico mining. Given the important role of alternative splicing in neural differentiation, there may be selective pressure to maintain a majority of splicing events in order to retain glial-like characteristics of the tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.